In this study, researchers aimed to examine trends in nonsurgical management and other treatment modalities in low-risk, HR-positive DCIS.

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe ...

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) ...

Daiichi Sankyo submits Enhertu sNDA in Japan as adjuvant therapy for patients with HER2 positive early breast cancer: Tokyo Monday, March 2, 2026, 12:00 Hrs [IST] Daiichi Sankyo h ...

The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Biopharma and ...

Crystalline polymers assembled inside tumor cell lysosomes rupture membranes, release iron, and trigger immune-activating ...

Researchers at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center uncovered new evidence that extra copies of a ...

Protara Therapeutics (NASDAQ:TARA) on February 23, 2026, announced updated interim data from its ongoing Phase 2 ADVANCED-2 trial evaluating intravesical TARA-002 in patients with high-risk non-muscle ...

Singular Genomics Launches G4X (TM) in the U.S., Delivering Industry-Leading Throughput for In Situ Multiomics, Targets Translational and Clinical Applications ...

GLP1-RA use may be linked to improved overall survival, but not improved disease-free survival, in breast cancer survivors, researchers report.